Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Metformin may delay prostate cancer progression, randomized trial suggests

Publish date:: September 20, 2020

Key clinical point: Adding metformin to standard care for advanced prostate cancer appeared to lengthen time to progression.

Major finding: The median time to progression to castration-resistant prostate cancer was 29 months with metformin plus standard therapy and 20 months with standard therapy alone (P = .01).

Study details: A randomized trial of 124 patients with high-risk locally advanced or metastatic hormone-sensitive prostate cancer.

Disclosures: There was no external funding for this study, and the investigators didn’t have any disclosures.

Citation:

ALGhandour R et al. ESMO 2020, Abstract 617MO.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,